Advanced melanoma survival improves significantly when immunotherapy is given before targeted therapy
A clinical trial showed a remarkable 20 percent advantage in the two-year overall survival rate for people with advanced melanoma who first received immunotherapy (72 percent survival rate) versus those who initially got targeted therapies (52 percent …